^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CDR101

    i
    Other names: CDR101, BCMAxCD3xPD-L1 trispecific antibody , CDR-101, CDR 101
    Associations

    News

    Trials
    Company:
    CDR-Life
    Drug class:
    PD-L1 inhibitor, BCMA inhibitor, T-cell stimulant, CD3 modulator
    Related drugs:
    Associations

    News

    Trials
    3years
    Preclinical Assessment of CDR101 – a BCMAxCD3xPD-L1 Trispecific Antibody with Superior Anti-Tumor Efficacy (ASH 2021)
    In contrast to high-affinity PD-L1 immune checkpoint inhibitors, CDR101 selectively inhibits PD-L1 at the immune synapse preventing on-target off-tumor effects. This is expected to translate into a decreased incidence of immune related adverse events (irAEs) and better efficacy arguing for a high clinical potential and swift translation into the clinic.
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    IL2RA (Interleukin 2 receptor, alpha) • SDC1 (Syndecan 1)
    |
    PD-L1 expression • SDC1 positive
    |
    CDR101